However, protein or mRNA expression of factors like excision repair cross-complementation group 1 (ERCC1) have not consistently been shown to correlate with response to Pt agents in NSCLC or BC [23–25]. This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.